Relay Therapeutics, Inc. Research and Development Expense
Relay Therapeutics, Inc. (RLAY) reported Research and Development Expense of $30.62 million for the 3-month period ending 2021-03-31, per its 10-Q filed 2021-05-13.
Discontinued › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2021-05-13
- Relay Therapeutics, Inc. research and development expense for the quarter ending 2021-03-31 was $30.62M, a 41.12% increase year-over-year.
- Relay Therapeutics, Inc. research and development expense for the quarter ending 2020-12-31 was $32.12M, a 43.36% increase year-over-year.
- Relay Therapeutics, Inc. research and development expense for the quarter ending 2020-09-30 was $24.38M, a 33.52% increase year-over-year.
- Relay Therapeutics, Inc. research and development expense for the quarter ending 2020-06-30 was $21.67M, a 32.13% increase year-over-year.
- Relay Therapeutics, Inc. research and development expense for fiscal 2020 was $99.86M, a 42.04% increase from fiscal 2019.
- Relay Therapeutics, Inc. research and development expense for fiscal 2019 was $70.31M.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2021-03-31 | $30.62M 10-Q · filed 2021-05-13 | $62.74M derived: sum of 2 quarters · filed 2021-05-13 | $87.12M derived: sum of 3 quarters · filed 2021-05-13 | $108.79M derived: sum of 4 quarters · filed 2021-05-13 |
| 2020-12-31 | $32.12M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-25 | $56.50M derived: sum of 2 quarters · filed 2021-03-25 | $78.17M derived: sum of 3 quarters · filed 2021-03-25 | $99.86M 10-K · filed 2021-03-25 |
| 2020-09-30 | $24.38M 10-Q · filed 2020-11-12 | $46.04M derived: sum of 2 quarters · filed 2020-11-12 | $67.74M 10-Q · filed 2020-11-12 | $90.15M derived: sum of 4 quarters · filed 2021-05-13 |
| 2020-06-30 | $21.67M 10-Q · filed 2020-08-27 | $43.36M 10-Q · filed 2020-08-27 | $65.77M derived: sum of 3 quarters · filed 2021-05-13 | $84.03M derived: sum of 4 quarters · filed 2021-05-13 |
| 2020-03-31 | $21.70M 10-Q · filed 2021-05-13 | $44.11M derived: sum of 2 quarters · filed 2021-05-13 | $62.36M derived: sum of 3 quarters · filed 2021-05-13 | $78.76M derived: sum of 4 quarters · filed 2021-05-13 |
| 2019-12-31 | $22.41M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-25 | $40.66M derived: sum of 2 quarters · filed 2021-03-25 | $57.06M derived: sum of 3 quarters · filed 2021-03-25 | $70.31M 10-K · filed 2021-03-25 |
| 2019-09-30 | $18.26M 10-Q · filed 2020-11-12 | $34.65M derived: sum of 2 quarters · filed 2020-11-12 | $47.90M 10-Q · filed 2020-11-12 | |
| 2019-06-30 | $16.40M 10-Q · filed 2020-08-27 | $29.64M 10-Q · filed 2020-08-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |